Arvest Bank Trust Division increased its stake in shares of Allergan PLC. (NYSE:AGN) by 1.1% during the second quarter, Holdings Channel reports. The firm owned 58,595 shares of the company’s stock after buying an additional 624 shares during the period. Arvest Bank Trust Division’s holdings in Allergan PLC. were worth $14,244,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. CAPROCK Group Inc. boosted its stake in shares of Allergan PLC. by 5.5% in the first quarter. CAPROCK Group Inc. now owns 1,095 shares of the company’s stock valued at $262,000 after buying an additional 57 shares during the period. Motco boosted its stake in shares of Allergan PLC. by 0.6% in the first quarter. Motco now owns 17,960 shares of the company’s stock valued at $4,291,000 after buying an additional 113 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $405,000. Rothschild Investment Corp IL boosted its stake in shares of Allergan PLC. by 15.6% in the first quarter. Rothschild Investment Corp IL now owns 10,654 shares of the company’s stock valued at $2,545,000 after buying an additional 1,436 shares during the period. Finally, Columbus Circle Investors bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $3,937,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allergan PLC. (AGN) traded down 0.35% during midday trading on Friday, reaching $223.99. 2,006,235 shares of the company were exchanged. The stock has a market capitalization of $74.88 billion, a price-to-earnings ratio of 6.82 and a beta of 1.16. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm’s 50-day moving average price is $243.31 and its 200 day moving average price is $238.68.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.35 EPS. Equities analysts predict that Allergan PLC. will post $16.27 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. Allergan PLC.’s dividend payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Position Raised by Arvest Bank Trust Division” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/19/allergan-plc-agn-position-raised-by-arvest-bank-trust-division.html.

A number of brokerages have issued reports on AGN. Mizuho restated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their target price on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and set a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. Allergan PLC. presently has a consensus rating of “Buy” and an average price target of $275.49.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.